首页> 美国卫生研究院文献>other >Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data
【2h】

Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data

机译:老年晚期骨髓增生异常综合症同种异体干细胞移植和非移植方法的比较:最佳统计方法和使用非随机化数据对临床结果进行的关键评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Allogeneic stem cell transplantation (ASCT) from related or unrelated donors may cure patients with myelodysplastic syndromes (MDS), a heterogeneous group of clonal stem cell disorders. We analysed 384 elderly patients (55-69 years) with advanced MDS who received either ASCT (n=247) and were reported to The European Group for Blood and Marrow Transplantation (EBMT) or a non –transplant approach (n=137) reported to the Düsseldorf registry. Besides an attempt to answer the question of „comparison“, the purpose of this work is to explain the difficulties in comparing a non-transplant with a transplant cohort, when death before transplant is likely but unknown and the selection of patients for transplant is based on assumptions. It shows which methods are almost always biased and that even the most sophisticated approaches crucially rely on clinical assumptions. Using the most appropriate model for our data, we derive an overall univariate non-significant survival disadvantage for the transplant cohort (HR: 1.29, p = 0.11). We show that such an “average” hazard ratio is however misleading due to non-proportionality of the hazards reflecting early treatment related mortality, the occurring of which is logically correlated with the interval between diagnosis and transplant creating a disproportional drop in the (reconstructed) survival curve of the transplanted patients. Also in multivariate analysis (correcting for age > 60 (HR: 1.4, p = 0.02) and abnormal cytogenetics (HR: 1.46, p = 0.01)), transplantation seems to be worse (HR: 1.39, p = 0.05) but only in the (incorrect but commonly applied) model without time varying covariates. The long term (time depending) hazard ratio is shown to be virtually 1 and overall survival is virtually identical in both groups. Nonetheless no conclusion can be reached from a clinical point of view without assumptions which are by their very nature untestable unless all patients would be followed from diagnosis.
机译:来自相关或不相关供体的同种异体干细胞移植(ASCT)可以治愈患有骨髓增生异常综合症(MDS)的患者,骨髓增生异常综合症是一组异种的克隆干细胞疾病。我们分析了384例老年MDS的老年患者(55-69岁),他们接受了ASCT(n = 247)并被报告给了欧洲血液和骨髓移植小组(EBMT)或非移植方法(n = 137)。进入杜塞尔多夫注册表。除了试图回答“比较”问题之外,这项工作的目的是解释在非移植患者与移植人群比较的情况下的困难,当移植前可能死亡但未知,并且选择移植患者的依据是根据假设。它显示了哪些方法几乎总是带有偏见,即使最复杂的方法也至关重要地依赖于临床假设。使用最合适的数据模型,我们得出了移植队列的总体单变量非显着生存不利因素(HR:1.29,p = 0.11)。我们表明,由于危害的非比例性反映了早期治疗相关的死亡率,因此这种“平均”危害比具有误导性,其发生与诊断和移植之间的间隔在逻辑上相关,从而导致(重建的)比例下降移植患者的生存曲线。同样在多变量分析(校正年龄> 60岁(HR:1.4,p = 0.02)和异常的细胞遗传学(HR:1.46,p = 0.01))中,移植似乎较差(HR:1.39,p = 0.05),但仅在(不正确但通常使用的)模型,且没有随时间变化的协变量。长期(视时间而定)危险比显示为1,而两组的总体生存率实际上是相同的。但是,从临床的角度来看,如果没有假设,除非所有患者都可以接受诊断,否则就其性质而言是无法检验的,因此无法得出任何结论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号